Febuxostat: drug review and update

Bibliography

• Edwards NL. Febuxostat: a new treatment for hyperuricaemia in gout. Rheumatology (Oxford) 2009;48(Suppl 2):ii15–19
   PubMed Web of Science ®Google Scholar
• Ernst ME, Fravel MA. Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout. Clin Ther 2009;31(11):2503-18
   PubMed Web of Science ®Google Scholar
• McCarty DJ. Crystals and arthritis. Dis Mon 1994;40(6):255-99
   PubMedGoogle Scholar
• Neogi T. Clinical practice. Gout. N Engl J Med 2011;364(5):443-52
   PubMed Web of Science ®Google Scholar
• Nuki G, Simkin PA. A concise history of gout and hyperuricemia and their treatment. Arthritis Res Ther 2006;8(Suppl 1):S1
   PubMed Web of Science ®Google Scholar
• Nuki G. Treatment of crystal arthropathy – history and advances. Rheum Dis Clin North Am 2006;32(2):333-57; vi
   PubMed Web of Science ®Google Scholar
• Richette P, Bardin T. Gout. Lancet 2010;375(9711):318-28
   PubMed Web of Science ®Google Scholar
• McCarty DJ. A historical note: Leeuwenhoek's description of crystals from a gouty tophus. Arthritis Rheum 1970;13:414-18
   PubMed Web of Science ®Google Scholar
• Becker MA, Jolly M. Hyperuricemia and associated diseases. Rheum Dis Clin North Am 2006;32(2):275-93; v-vi
   PubMed Web of Science ®Google Scholar
• Choi HK, Mount DB, Reginato AM, American College of Physicians & American Physiological Society. Pathogenesis of gout. Ann Intern Med 2005;143(7):499-516
   PubMed Web of Science ®Google Scholar
• Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum 2004;51(3):321-5
   PubMed Web of Science ®Google Scholar
• Firestein GS, Budd RC, Harris ED, et al. Kelley's textbook of rheumatology. 9th edition. Saunders Elsevier, Waltham, MA, USA; 2013
   Google Scholar
• Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med 1987;82:421-6
   PubMedGoogle Scholar
• Schlesinger N. Management of acute and chronic gouty arthritis: present state-of-the-art. Drugs 2004;64(21):2399-416
   PubMed Web of Science ®Google Scholar
• Feig DI. Uric acid: a novel mediator and marker of risk in chronic kidney disease? Curr Opin Nephrol Hypertens 2009;18(6):526-30
   PubMed Web of Science ®Google Scholar
• Choi HK. A prescription for lifestyle change in patients with hyperuricemia and gout. Curr Opin Rheumatol 2010;22(2):165-72
   PubMed Web of Science ®Google Scholar
• Choi HK, Ford ES, Li C, Curhan G. Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2007;57(1):109-15
   PubMed Web of Science ®Google Scholar
• Zhang Y, Woods R, Chaisson CE, et al. Alcohol consumption as a trigger of recurrent gout attacks. Am J Med 2006;119(9):800.e13-18
   PubMedGoogle Scholar
• Rathmann W, Funkhouser E, Dyer AR, Roseman JM. Relations of hyperuricemia with the various components of the insulin resistance syndrome in young black and white adults: the CARDIA study. Coronary Artery Risk Development in Young Adults. Ann Epidemiol 1998;8(4):250-61
   PubMed Web of Science ®Google Scholar
• Nakaya I, Namikoshi T, Tsuruta Y, Dialysis Physicians. Management of asymptomatic hyperuricaemia in patients with chronic kidney disease by Japanese nephrologists: a questionnaire survey. Nephrology (Carlton) 2011;16(5):518-21
   PubMed Web of Science ®Google Scholar
• Ghaemi-Oskouie F, Shi Y. The role of uric acid as an endogenous danger signal in immunity and inflammation. Curr Rheumatol Rep 2011;13(2):160-6
   PubMed Web of Science ®Google Scholar
• Martinon F, Petrilli V, Mayor A, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006;440(7081):237-41
   PubMed Web of Science ®Google Scholar
• Choi H. Epidemiology of crystal arthropathy. Rheum Dis Clin North Am 2006;32(2):255-73
   PubMed Web of Science ®Google Scholar
• Chohan S, Becker MA. Update on emerging urate-lowering therapies. Curr Opin Rheumatol 2009;21(2):143-9
   PubMed Web of Science ®Google Scholar
• Adams PF, Hendershot GE, Marano MA, Centers for Disease Control & Prevention/National Center for Health Statistics. Current estimates from the National Health Interview Survey, 1996. Vital Health Stat 1999;10(200):1-203
   Google Scholar
• Weaver AL. Epidemiology of gout. Cleve Clin J Med 2008;75(Suppl 5):S9-12
   PubMedGoogle Scholar
• Kramer HM, Curhan G. The association between gout and nephrolithiasis: the National Health and Nutrition Examination Survey III, 1988-1994. Am J Kidney Dis 2002;40(1):37-42
   PubMed Web of Science ®Google Scholar
• Lawrence RC, Felson DT, Helmick CG, et al.; National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 2008;58(1):26-35
   PubMed Web of Science ®Google Scholar
• Dehghan A, Kottgen A, Yang Q, et al. Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. Lancet 2008;372(9654):1953-61
   PubMed Web of Science ®Google Scholar
• Riches PL, Wright AF, Ralston SH. Recent insights into the pathogenesis of hyperuricaemia and gout. Hum Mol Genet 2009;18(R2):R177-84
   PubMedGoogle Scholar
• Emmerson BT, Nagel SL, Duffy DL, Martin NG. Genetic control of the renal clearance of urate: a study of twins. Ann Rheum Dis 1992;51(3):375-7
   PubMed Web of Science ®Google Scholar
• Wilk JB, Djousse L, Borecki I, et al. Segregation analysis of serum uric acid in the NHLBI Family Heart Study. Hum Genet 2000;106(3):355-9
   PubMed Web of Science ®Google Scholar
• Anderson A, Singh JA. Pegloticase for chronic gout. Cochrane Database Syst Rev 2010;(3):CD008335
   Google Scholar
• Zhang W, Doherty M, Bardin T, et al.; EULAR Standing Committee for International Clinical Studies Including Therapeutics. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65(10):1312-24
   PubMed Web of Science ®Google Scholar
• Jordan KM, Cameron JS, Snaith M, et al.; Audit Working Group. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford) 2007;46(8):1372-4
   PubMed Web of Science ®Google Scholar
• Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005;353(23):2450-61
   PubMed Web of Science ®Google Scholar
• Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, et al. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis 1998;57(9):545-9
   PubMed Web of Science ®Google Scholar
• Sarawate CA, Brewer KK, Yang W, et al. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc 2006;81(7):925-34
   PubMed Web of Science ®Google Scholar
• Singh JA, Hodges JS, Asch SM. Opportunities for improving medication use and monitoring in gout. Ann Rheum Dis 2009;68(8):1265-70
   PubMed Web of Science ®Google Scholar
• Dalbeth N, Stamp L. Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events. Semin Dial 2007;20(5):391-5
   PubMed Web of Science ®Google Scholar
• Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984;76(1):47-56
   PubMed Web of Science ®Google Scholar
• Riedel AA, Nelson M, Joseph-Ridge N, et al. Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims. J Rheumatol 2004;31(8):1575-81
   PubMed Web of Science ®Google Scholar
• Wortmann RL. Gout and hyperuricemia. Curr Opin Rheumatol 2002;14(3):281-6
   PubMed Web of Science ®Google Scholar
• Arellano F, Sacristan JA. Allopurinol hypersensitivity syndrome: a review. Ann Pharmacother 1993;27(3):337-43
   PubMed Web of Science ®Google Scholar
• Reinders MK, Haagsma C, Jansen TL, et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout. Ann Rheum Dis 2009;68(6):892-7
   PubMed Web of Science ®Google Scholar
• Terkeltaub R. Update on gout: new therapeutic strategies and options. Nat Rev Rheumatol 2010;6(1):30-8
   PubMed Web of Science ®Google Scholar
• Gratton SB, Scalapino KJ, Fye KH. Case of anakinra as a steroid-sparing agent for gout inflammation. Arthritis Rheum 2009;61(9):1268-70
   PubMed Web of Science ®Google Scholar
• Singh D, Huston KK. IL-1 inhibition with anakinra in a patient with refractory gout. J Clin Rheumatol 2009;15(7):366
   PubMed Web of Science ®Google Scholar
• McGonagle D, Tan AL, Shankaranarayana S, et al. Management of treatment resistant inflammation of acute on chronic tophaceous gout with anakinra. Ann Rheum Dis 2007;66(12):1683-4
   PubMed Web of Science ®Google Scholar
• So A, De Smedt T, Revaz S, Tschopp J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007;9(2):R28
   PubMed Web of Science ®Google Scholar
• Mitha E, Schumacher HR, Fouche L, et al. Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial. Rheumatology (Oxford) 2013;52(7):1285-92
   PubMed Web of Science ®Google Scholar
• Terkeltaub R, Sundy JS, Schumacher HR, et al. The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study. Ann Rheum Dis 2009;68(10):1613-17
   PubMed Web of Science ®Google Scholar
• Chen K, Fields T, Mancuso CA, et al. Anakinra's efficacy is variable in refractory gout: report of ten cases. Semin Arthritis Rheum 2010;40(3):210-14
   PubMed Web of Science ®Google Scholar
• Schumacher HR Jr. Febuxostat: a non-purine, selective inhibitor of xanthine oxidase for the management of hyperuricaemia in patients with gout. Expert Opin Investig Drugs 2005;14(7):893-903
   PubMed Web of Science ®Google Scholar
• Takano Y, Hase-Aoki K, Horiuchi H, et al. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase. Life Sci 2005;76(16):1835-47
   PubMed Web of Science ®Google Scholar
• Okamoto K, Eger BT, Nishino T, et al. An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition. J Biol Chem 2003;278(3):1848-55
   PubMed Web of Science ®Google Scholar
• Khosravan R, Kukulka MJ, Wu JT, et al. The effect of age and gender on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. J Clin Pharmacol 2008;48(9):1014-24
   PubMed Web of Science ®Google Scholar
• Mayer MD, Khosravan R, Vernillet L, et al. Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment. Am J Ther 2005;12(1):22-34
   PubMedGoogle Scholar
• Becker MA, Kisicki J, Khosravan R, et al. Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers. Nucleosides Nucleotides Nucleic Acids 2004;23(8-9):1111-16
   PubMed Web of Science ®Google Scholar
• Uloric Package insert. Takeda Pharmaceuticals America, Inc., Deerfield: Ill; 2009
   Google Scholar
• Bruce SP. Febuxostat: a selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout. Ann Pharmacother 2006;40:2187-94
   PubMed Web of Science ®Google Scholar
• Grabowski B, Khosravan R, Wu JT, et al. Effect of hydrochlorothiazide on the pharmacokinetics and pharmacodynamics of febuxostat, a non-purine selective inhibitor of xanthine oxidase. Br J Clin Pharmacol 2010;70(1):57-64
   PubMed Web of Science ®Google Scholar
• Grabowski BA, Khosravan R, Vernillet L, Mulford DJ. Metabolism and excretion of [14C] febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase, in healthy male subjects. J Clin Pharmacol 2011;51(2):189-201
   PubMed Web of Science ®Google Scholar
• Osada Y, Tsuchimoto M, Fukushima H, et al. Hypouricemic effect of the novel xanthine oxidase inhibitor, TEI-6720, in rodents. Eur J Pharmacol 1993;241(2-3):183-8
   PubMed Web of Science ®Google Scholar
• Mukoyoshi M, Nishimura S, Hoshide S, et al. In vitro drug-drug interaction studies with febuxostat, a novel non-purine selective inhibitor of xanthine oxidase: plasma protein binding, identification of metabolic enzymes and cytochrome P450 inhibition. Xenobiotica 2008;38(5):496-510
   PubMed Web of Science ®Google Scholar
• Horiuchi H, Ota M, Kobayashi M, et al. A comparative study on the hypouricemic activity and potency in renal xanthine calculus formation of two xanthine oxidase/xanthine dehydrogenase inhibitors: TEI-6720 and allopurinol in rats. Res Commun Mol Pathol Pharmacol 1999;104(3):307-19
   PubMed Web of Science ®Google Scholar
• Khosravan R, Grabowski BA, Mayer MD, et al. The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. J Clin Pharmacol 2006;46(1):88-102
   PubMed Web of Science ®Google Scholar
• Khosravan R, Wu JT, Joseph-Ridge N, Vernillet L. Pharmacokinetic interactions of concomitant administration of febuxostat and NSAIDs. J Clin Pharmacol 2006;46(8):855-66
   PubMed Web of Science ®Google Scholar
• Khosravan R, Mayer MD, Wu JT, et al. Effect of concomitant administration of febuxostat and colchicine on pharmacokinetics of febuxostat and colchicine at steady state. Arthritis Rheum 2005;52:S102-3
   Web of Science ®Google Scholar
• Khosravan RP, Erdman KB, Vernillet LPP, et al. Effect of febuxostat on pharmacokinetics of desipramine, a CYP2D6 substrate, in healthy subjects. Clin Pharmacol Ther 2005;77:P43-3
   PubMed Web of Science ®Google Scholar
• Grabowski BA, Khosravan R, Wu JT, et al. Effect of hydrochlorothiazide on pharmacokinetics and pharmacodynamics of febuxostat. Arthritis Rheum 2005;52:S103-4
   Web of Science ®Google Scholar
• Komoriya K, Osada Y, Hasegawa M, et al. Hypouricemic effect of allopurinol and the novel xanthine oxidase inhibitor TEI-6720 in chimpanzees. Eur J Pharmacol 1993;250(3):455-60
   PubMed Web of Science ®Google Scholar
• Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum 2005;52(3):916-23
   PubMedGoogle Scholar
• Schumacher HR Jr, Becker MA, Wortmann RL, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 2008;59(11):1540-8
   PubMed Web of Science ®Google Scholar
• Naoyuki K, Shin F, Toshikazu H, et al. Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in Japan: late phase 2 clinical study. J Clin Rheumatol 2011;17(4 Suppl 2):S35-43
   PubMed Web of Science ®Google Scholar
• Becker MA, Schumacher HR, Espinoza LR, et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther 2010;12(2):R63
   PubMed Web of Science ®Google Scholar
• Schumacher HR Jr, Becker MA, Lloyd E, et al. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford) 2009;48(2):188-94
   PubMed Web of Science ®Google Scholar
• Becker MA, Schumacher HR, MacDonald PA, et al. Clinical efficacy and safety of successful long term urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol 2009;36(6):1273-82
   PubMed Web of Science ®Google Scholar
• Singh JA. Advances in gout: some answers, more questions. Arthritis Res Ther 2010;12(5):136
   PubMedGoogle Scholar
• Komoriya K, Hoshide S, Takeda K, et al. Pharmacokinetics and pharmacodynamics of febuxostat (TMX-67), a non-purine selective inhibitor of xanthine oxidase/xanthine dehydrogenase (NPSIXO) in patients with gout and/or hyperuricemia. Nucleosides Nucleotides Nucleic Acids 2004;23(8-9):1119-22
   PubMed Web of Science ®Google Scholar
• Whelton A, Macdonald PA, Zhao L, et al. Renal function in gout: long-term treatment effects of febuxostat. J Clin Rheumatol 2011;17(1):7-13
   PubMed Web of Science ®Google Scholar
• Jansen TL, Richette P, Perez-Ruiz F, et al. International position paper on febuxostat. Clin Rheumatol 2010;29(8):835-40
   PubMed Web of Science ®Google Scholar
• Jackson RL, Hunt B, MacDonald PA. The efficacy and safety of febuxostat for urate lowering in gout patients >/=65 years of age. BMC Geriatr 2012;12:11
   PubMed Web of Science ®Google Scholar
• Wortmann RL, Macdonald PA, Hunt B, Jackson RL. Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials. Clin Ther 2010;32(14):2386-97
   PubMed Web of Science ®Google Scholar
• Khanna D, Fitzgerald JD, Khanna PP, et al. American College of Rheumatology. American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) 2012;64(10):1431-46
   PubMed Web of Science ®Google Scholar
• Khanna D, Khanna PP, Fitzgerald JD, et al. American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. American College of Rheumatology. Arthritis Care Res (Hoboken) 2012;64(10):1447-61
   PubMed Web of Science ®Google Scholar